Cargando…
Bone Targeting Agents in Patients with Metastatic Prostate Cancer: State of the Art
SIMPLE SUMMARY: Over the disease course of metastatic prostate cancer, approximately the 90% of patients develops bone metastases, with bone involvement frequently leading to various skeletal complications including pathological fractures, spinal cord compression, and pain. Notably enough, the pecul...
Autores principales: | Mollica, Veronica, Rizzo, Alessandro, Rosellini, Matteo, Marchetti, Andrea, Ricci, Angela Dalia, Cimadamore, Alessia, Scarpelli, Marina, Bonucci, Chiara, Andrini, Elisa, Errani, Costantino, Santoni, Matteo, Montironi, Rodolfo, Massari, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867059/ https://www.ncbi.nlm.nih.gov/pubmed/33535541 http://dx.doi.org/10.3390/cancers13030546 |
Ejemplares similares
-
An Insight on Novel Molecular Pathways in Metastatic Prostate Cancer: A Focus on DDR, MSI and AKT
por: Mollica, Veronica, et al.
Publicado: (2021) -
Treating Prostate Cancer by Antibody–Drug Conjugates
por: Rosellini, Matteo, et al.
Publicado: (2021) -
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming?
por: Marchetti, Andrea, et al.
Publicado: (2022) -
The Molecular Characteristics of Non-Clear Cell Renal Cell Carcinoma: What’s the Story Morning Glory?
por: Marchetti, Andrea, et al.
Publicado: (2021) -
TNM staging towards a personalized approach in metastatic urothelial carcinoma: what will the future be like?—a narrative review
por: Rizzo, Alessandro, et al.
Publicado: (2021)